Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03270709 · ClinicalTrials.gov registry record · Phase 1
Effect of High-Dose Vitamin D3 in Smokers and Non-Smokers With and Without HIV
A Phase 1 study, sponsored by Emory University.
- Terminated
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
NCT03270709 is a Phase 1 study that was terminated before completion, run by Emory University. The registered enrollment target is 7 participants.
The verdict
NCT03270709, a Phase 1 study, was terminated before completion, sponsored by Emory University.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
Supplementation with vitamin D improves HIV+ macrophages phagocytosis in vitro. There is evidence to suggest that administering vitamin D can in fact improve immune function in individuals. The study will evaluate the impact of high dose vitamin D in HIV+ smokers' and HIV- smokers' in vivo. The primary goal is to improve innate immune host response to infection in patients already at high risk by virtue of HIV and smoking status.
Interventions
- DRUG Vitamin D3 450,000 IU orally
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2018-04-11 |
| Est. Completion | 2018-10-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03270709
The ClinicalTrials.gov registry entry for NCT03270709 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Vitamin D3 450,000 IU orally is the first listed.
NCT03270709 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03270709 about?
NCT03270709 is a clinical study titled "Effect of High-Dose Vitamin D3 in Smokers and Non-Smokers With and Without HIV". Supplementation with vitamin D improves HIV+ macrophages phagocytosis in vitro. There is evidence to suggest that administering vitamin D can in fact improve immune function in individuals. The study will evaluate the impact of high dose vitamin D in HIV+ smokers' and HIV- smokers' in vivo. The prim...
What is the current status of trial NCT03270709?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2018-04-11. Estimated completion is 2018-10-15.
What interventions are being tested in trial NCT03270709?
The interventions under investigation include: Vitamin D3 450,000 IU orally (DRUG).
Who is sponsoring clinical trial NCT03270709?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.